key: cord-0895562-0pxg1zn3
authors: Khaitov, Musa; Nikonova, Alexandra; Shilovskiy, Igor; Kozhikhova, Ksenia; Kofiadi, Ilya; Vishnyakova, Lyudmila; Nikolskii, Alexander; Gattinger, Pia; Kovchina, Valeria; Barvinskaia, Ekaterina; Yumashev, Kirill; Smirnov, Valeriy; Maerle, Artem; Kozlov, Ivan; Shatilov, Artem; Timofeeva, Anastasiia; Andreev, Sergey; Koloskova, Olesya; Kuznetsova, Nadezhda; Vasina, Daria; Nikiforova, Maria; Rybalkin, Sergei; Sergeev, Ilya; Trofimov, Dmitriy; Martynov, Alexander; Berzin, Igor; Gushchin, Vladimir; Kovalchuk, Aleksey; Borisevich, Sergei; Valenta, Rudolf; Khaitov, Rakhim; Skvortsova, Veronica
title: Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation
date: 2021-05-10
journal: Allergy
DOI: 10.1111/all.14850
sha: c8bd2cfbf3d0d6e9d90d5b4c61be5fc4ec4b3d19
doc_id: 895562
cord_uid: 0pxg1zn3

BACKGROUND: First vaccines for prevention of Coronavirus disease 2019 (COVID‐19) are becoming available but there is a huge and unmet need for specific forms of treatment. In this study we aimed to evaluate the anti‐SARS‐CoV‐2 effect of siRNA both in vitro and in vivo. METHODS: To identify the most effective molecule out of a panel of 15 in silico designed siRNAs, an in vitro screening system based on vectors expressing SARS‐CoV‐2 genes fused with the firefly luciferase reporter gene and SARS‐CoV‐2‐infected cells was used. The most potent siRNA, siR‐7, was modified by Locked nucleic acids (LNAs) to obtain siR‐7‐EM with increased stability and was formulated with the peptide dendrimer KK‐46 for enhancing cellular uptake to allow topical application by inhalation of the final formulation – siR‐7‐EM/KK‐46. Using the Syrian Hamster model for SARS‐CoV‐2 infection the antiviral capacity of siR‐7‐EM/KK‐46 complex was evaluated. RESULTS: We identified the siRNA, siR‐7, targeting SARS‐CoV‐2 RNA‐dependent RNA polymerase (RdRp) as the most efficient siRNA inhibiting viral replication in vitro. Moreover, we showed that LNA‐modification and complexation with the designed peptide dendrimer enhanced the antiviral capacity of siR‐7 in vitro. We demonstrated significant reduction of virus titer and lung inflammation in animals exposed to inhalation of siR‐7‐EM/KK‐46 in vivo. CONCLUSIONS: Thus, we developed a therapeutic strategy for COVID‐19 based on inhalation of a modified siRNA‐peptide dendrimer formulation. The developed medication is intended for inhalation treatment of COVID‐19 patients.

In December 2019, an outbreak of severe acute respiratory infections was reported in the Chinese city of Wuhan. In the meantime, the disease named COVID-19 (CoronaVirus Disease-19) has flooded the globe and became the deadliest respiratory disease pandemic since 1918 when the Spanish influenza pandemic killed more than 50 million people. 1, 2 The culprit of the current COVID-19 pandemic outbreak is the novel coronavirus (CoV) which was named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV). SARS-CoV-2 such as SARS-CoV and MERS-CoV which all can cause severe respiratory illness belong to the closely related ß-corona viruses 3 and have originated as human pathogens by animal-to-human-host switching. 4 The two SARS viruses are derived from viruses enzootic in bats for which a rich reservoir exists in Asian countries and in particular in China. 5 As of March 3, 2021 , there are >115 million confirmed cases and >2.5 million deaths related to COVID-19 according to the Johns Hopkins Coronavirus Resource Center (https://coron avirus.jhu.edu/map.html). Currently, multiple vaccine candidates have entered into clinical trials, some of them have already been approved by health authorities and recently vaccination has been started in several countries. [6] [7] [8] [9] However, in addition to prophylactic vaccines SARS-CoV-2specific therapies for treatment of infected patients are urgently needed. Accordingly, several antiviral drugs, among them remdesivir, hydroxychloroquine, lopinavir and interferons, have been evaluated for treatment of COVID-19 but so far with limited clinical success. 10, 11 Convalescent plasma treatment is another possibility for treatment of severe COVID-19 12 and achieved FDA approval for treatment of critically ill patients but there are limitations to its production. 13 In addition, first monoclonal SARS-CoV-2-specific antibodies have been developed, showed first promising results in experimental animal models 14 and reduced viral loads in patients. 15 Therefore, a huge unmet need for SARS-CoV-2-specific treatment strategies remains.

The SARS-CoV-2 viral genome is a single-stranded positive RNA (+ssRNA) of almost 30 kb, encoding at least five open reading frames (ORFs). The first ORF (ORF1a/b) occupies about 70% of the entire genome and encodes 16 nonstructural proteins (nsp1- 16) . The remaining 30% of the genome encodes four major structural proteins necessary for virion assembly: spike (S), membrane (M), envelope (E), and nucleocapsid (N). [16] [17] [18] Gene expression in general and viral gene expression in infectious diseases can be suppressed through the mechanism of RNA interference (RNAi) for therapeutic purposes. [19] [20] [21] [22] [23] The RNAi approach is based on negative regulation of gene expression at the post-transcriptional level and therefore highly specific. 24, 25 Hence, the main advantage of the RNAi strategy over most other therapeutic approaches is its specificity but the technology has also limitations among them how to enhance specific targeting of and efficient transportation into infected cells.

In this study we screened a panel of SARS-CoV-2-specific siRNAs for their potential to silence SARS-CoV-2 gene expression. The most potent silencing siRNA was then modified to enhance siRNA stability and formulated with a novel non-toxic peptide dendrimer KK-46 as vehicle for efficient siRNA delivery into the target cells. Finally, we show in an in vivo model of SARS-CoV-2 infection in Syrian hamsters 26 that topical treatment by inhalation of the modified siRNA-peptide dendrimer formulation has the potential to reduce viral replication and to ameliorate SARS-CoV-2-induced lung inflammation.

The primary screening of siRNAs silencing activity was performed Table S1 .siRNA against firefly luciferase (siLuc) 27 and GFP were used as controls.

To increase stability, we incorporated LNA (locked nucleic acid)modifications to the 3' ends of the siR-7 sense (S) and antisense sequences (aS) as follow (LNA; symbols of bases, +G and+T), 5'-3': S +Ggaaggaaguucuguugaa+T+Tt aS uucaacagaacuuccuucc+T+Tt

HEp-2 cells (ATCC® Number: CCL-23™) were cultivated with 10% fetal bovine serum (FBS) (HyClone, US) and 1% penicillin/ streptomycin (PS; PanEco, Russia) in Dulbecco's modified Eagle's medium (DMEM; PanEco, Russia). The cells were seeded into 24well plates at a concentration of 10 5 cells/well in 0.5 mL of media and incubated at 37°C with 5% CO 2 for 12-24 h. The cells were consistently co-transfected with each of the plasmid constructs Cells transfected with siLuc and siGFP were used as a positive and negative control, respectively.

Vero cells were seeded into 96-well cell culture plates (NUNC, Denmark) at 2 × 10 5 cells/mL with 5% FBS, allowed to attach and grow for 24 h, and treated with 2-fold dilutions of KK-46 (29- 2500 μg/mL) in FBS-free culture media for 24 h. The cytotoxicity of KK-46 was assessed using "CellTiter96® Non-Radioactive Cell Proliferation Assay" kit (Promega, USA) in accordance with the manufacturer's instructions. The absorbance was recorded at 570 nm wavelength (with reference wavelength 700 nm).

All measurements were performed with the Varioskan®Flash 2.4 spectral scanning multimode reader (Thermo Fisher Scientific, USA).

The design of the cationic dendrimeric peptide KK-46 for intracellu- Figure S1 -S3). The peptide was tested for its ability to inhibit the binding of RBD to ACE2 using a molecular interaction assay. 28

The HEp-2 cells were propagated as described above. Cells were transfected with the pGL3 Luciferase Reporter Vector (Promega) 

The SARS-CoV-2 strain PMVL-1 (GISAID Number Figure S4 ).

Duplexes of siRNA (siR-7) and siLNA (siR-7-EM) (3 μg) were incubated at 37°C in 50% FBS (Invitrogen) diluted in phosphate buffered saline for 264 h. Aliquots of 10 μg were withdrawn at indicated time points and stored at −20°C. Samples were then subjected to electrophoresis in a 1.5% agarose gel, stained with Ethidium Bromide and bands corresponding to full-length siRNAs were quantified by gel densitometry using Gel Doc XR+software (BioRad, USA) and compared to the sample collected immediately after dissolving the siRNA in the FBS solution. Lung tissues were freshly fixed in 10% buffered formaldehyde, embedded in paraffin wax, and stained with haematoxylin-eosin (H&E).

The histopathological changes were graded according to a modified semiquantitative scoring system by a blinded investigator (none, 0; mild, 1.0; moderate, 2.0; or severe, 3.0). The right lobe of the lung was homogenated and the viral titer was assessed by plaque assay to determine the number of PFU as described. 29 Five animals left in each group were exposed to the siR-7-EM/KK-46 aerosol at days 3, 4, 5 and were sacrificed at day 6 after infection. Lungs were removed and processed as described above.

The second series of in vivo experiments were performed according to the same scheme with two exceptions. First, we exposed anesthetized animals to siR-7-EM/KK-46 aerosol twice a day with two hours interval to yield a daily dose of the antiviral complexes of 0.35, 0.7 and 2.0 mg/kg, respectively. Second, the control group of animals received orally Favipiravir (within 1 hour after infection, a dose of 1.2 mg/animal was administered twice a day, and then daily for 6 days post infection 0.4 mg/animal were given twice a day).

According to the manufacturer's instruction Favipiravir was administered perorally. The pills were resuspended in a 1% starch solution (w/v, dissolved in distilled boiled water) and given to Hamsters without prior anesthesia. The efficacy of Favipiravir was assessed as described for siR-7-EM/KK-46.

The Shapiro-Wilk test for normality was performed. Data were presented as means +s.e.m for parametric analyses and as medians +s.d. for nonparametric analyses, as indicated in the figure legends.

Statistical analyses were performed using Prism version 8 (GraphPad Software). For normally distributed data we performed ordinary oneway ANOVA or one-way repeated measures ANOVA with Tukey's or Dunnetts's post hoc tests, respectively, for multiple comparisons to determine differences between groups, or if not normally distributed the Kruskal-Wallis test followed by post hoc testing (if the Kruskal-Wallis was significant) using un-paired Mann-Whitney U tests was performed, as mentioned in the respective figure legends. Data were accepted as significantly different when p < 0.05. siRNA against luciferase (siLuc) and GFP (siGFP) were used as a positive and negative control, respectively. As indicated in Table 1 and Figure 2 the siRNAs siN-4, siR-7 and siR-11 which significantly decreased the level of luminescence for more than 80% were chosen as the most potent SARS-CoV-2 silencing siRNAs and were further studied. Of note, we found no significant difference in luciferase expression between cells transfected with plasmid only or after cotransfection with plasmid and non-specific siGFP (Table 1 ).

Next, we investigated the antiviral effects of the three selected siRNAs (siN-4, siR-7 and siR-11) in vitro. To evaluate their antiviral effect, we transfected Vero E6 cells with complexes of siRNA/ Lipofectamine 3000 and four hours after transfection cells were infected with SARS-CoV-2 at MOI 0.0001. After 48 hours of infection cells were lysed and viral load was determined by qRT-PCR.

We found a significant difference in vRNA concentration between cells treated with specific siR-7, compared to both unspecific siLuctransfected and infected cells (p < 0.05) (Figure 2c ). In addition, a significant reduction of vRNA in cells treated with siN-4 (p < 0.05) compared to SARS-CoV-2 infected cells and a trend towards significance (p = 0.0571) to reduce the amount of vRNA compared to unspecific siLuc-transfected cells were observed. According to these results the siR-7 targeting SARS-CoV-2 RdRp gene was chosen as best candidate for further analysis.

Introduction of LNA into classic antisense oligos has been shown to increase their stability. 30 

In Again, we performed scoring of lung pathology and found significantly (p < 0.01) decreased lung inflammation in animals exposed to 2 mg/kg of siR-7-EM/KK-46 aerosol compared with SARS-CoV-2 infected group at day six but not in the animals treated with lower doses of siR-7-EM/KK-46 or with Favipiravir as compared to the infected but untreated animals ( Figure S6b ). However, this significant reduction was only found after 6 days suggesting that the dose should be 2 mg/kg or higher. Research in COVID-19 is rapidly expanding. First approaches for siRNA treatment have been described 44 but to the best of our knowledge our study as summarized in Figure S7 is the first which aimed not only to evaluate the antiviral efficiency of siRNAs targeting the SARS-CoV-2 genome but also sought to overcome possible bottlenecks of a therapeutic SARS-CoV-2 siRNA approach.

Designing siRNAs with antiviral activity is a challenging task. 45 First, sequences of siRNAs must be identified which are highly specific minimizing potential off-target effects and are highly effective in silencing. Second, effective and safe forms of delivery must be de- In addition to identifying KK-46 as a possible pharmacologically acceptable vehicle for in vivo use we also tried to optimize the siR-7 molecule itself. It has been shown that potential off-target effects and unwanted immunostimulatory effects of siRNAs as well as their biodegradation may be reduced by incorporation of Locked nucleic acids (LNAs) in the siRNA sequence. LNA nucleotides contain a methylene linkage connecting the 2' oxygen and 4' carbon of the ribose ring that leads to a reduction of the conformational flexibility of the ribose. 55 siRNA molecules have the potential to induce inflammatory response by effects on the innate immune system through activation of Toll-like receptors. 56 LNA incorporation has been shown to inhibit such immune stimulation. In particular, LNA modification at the 3′ end of the siRNA passenger strand, strongly inhibited IFNα induction without affecting knockdown activity. 57 Moreover LNAincorporation can increase endo-and exo-nuclease resistance and sequence-related off-target effects. 58 We therefore incorporated LNA-modification to the 3' ends of siR-7 sense and antisense sequences to improve it stability and functionality and found that this significantly increases the half-life compared with unmodified siRNA ( Figure 3 ). Next, we investigated whether the LNA-modification may have a negative influence on the knockdown efficacy. For this purpose, we transfected Vero E6 cells with unmodified siR-7 or LNAmodified siR-7-EM/peptide dendrimer complex at three increasing concentrations of siRNA/siLNA and KK-46 ( Figure 4 ). We found that LNA-modification did not affect specific virus gene silencing which is in accordance with a previous study. 58 It has been demonstrated that there is a sequence-and target-independent effect by siRNA via toll-like receptor 3 (TLR3). 59 However, the experiments carried out in SARS-CoV-2-infected Vero cells expressing TLR3 in Figure 4 with the control siRNA siLuc demonstrate that there is no such TLR3mediated non-specific effect. We thus could establish a formulation of LNA-modified siR-7-EM targeted to RdRp gene of SARS-CoV-2 in complex with the KK-46 peptide dendrimer which revealed strong and specific antiviral activity in vitro.

Topically applied siRNAs have been shown to be highly effective for inhibition of herpes simplex virus (HSV) and RSV in animal models. 60, 61 We therefore envisaged topical treatment in the lung by inhalation for the treatment of COVID-19. Furthermore, the lung is a major target for the disease due to high expression of ACE2 and long-term lung damage is a major complication of COVID-19. 62

Moreover, nebulizers or inhalers are available to generate aerosols for drug delivery by inhalation. 63 For the in vivo studies we used the model based on Syrian hamsters which has been shown to be a suitable small animal model for COVID-19 64 and was also used to evaluate the effects of 

This study was funded by Federal Medico-biological Agency of Russia. We are grateful to Prof. Andrew Fire, Stanford University for having critically read our manuscript. 

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

The hallmarks of COVID-19 disease

Emerging infections: a perpetual challenge

The origin of COVID-19 and why it matters

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

SARS-CoV-2 vaccines in development

Repurposed Antiviral Drugs for Covid-19 -Interim WHO solidarity trial results

Remdesivir for the treatment of Covid-19 -final report

Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study

Covid-19: FDA approves use of convalescent plasma to treat critically ill patients

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19

Mechanisms of SARS-CoV-2 transmission and pathogenesis

Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform

Coronavirus biology and replication: implications for SARS-CoV-2

Gene silencing in mammals by small interfering RNAs

Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5

Medicine: silencing viruses with RNA

Modulation of HIV-1 replication by RNA interference

RNA-dependent RNA polymerases, viruses, and RNA silencing

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

RNA interference: biology, mechanism, and applications

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Water-soluble N-[(2-hydroxy-3-trimethylammonium) propyl]chitosan chloride as a nucleic acids vector for cell transfection

Antibodies in serum of convalescent patients following mild COVID-19 do not always prevent virus-receptor binding

Inventor composition of agar coating for titration of coronavirus-the causative agent of severe acute respiratory syndrome by plaque forming units

Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo

Positional effect of chemical modifications on short interference RNA activity in mammalian cells

RNA secondary structure motifs of the influenza a virus as targets for siRNA-mediated RNA interference

COVID-19: The first documented coronavirus pandemic in history

Clinical efficacy of antivirals against novel coronavirus (COVID-19): A review

Clinical advances of siRNA therapeutics

RNA Interference as a prospective tool for the control of human viral infections

siRNA targeting the leader sequence of SARS-CoV inhibits virus replication

Attenuation of SARS coronavirus by a short hairpin RNA expression plasmid targeting RNA-dependent RNA polymerase

Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference

Inhibition of SARS-associated coronavirus infection and replication by RNA interference

Application of siRNA against SARS in the rhesus macaque model

Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque

Computational identification of small interfering RNA targets in SARS-CoV-2

Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics

Design of small interfering RNAs for antiviral applications

The siRNAbased drug for inhibition of the SARS-CoV-2 replication

Pulmonary delivery of therapeutic siRNA

Small interfering RNAs targeted to interleukin-4 and respiratory syncytial virus reduce airway inflammation in a mouse model of virus-induced asthma exacerbation

Respiratory syncytial virus upregulates IL-33 expression in mouse model of virus-induced inflammation exacerbation in OVA-sensitized mice and in asthmatic subjects

Dendrimers as pharmaceutical excipients: synthesis, properties. toxicity and biomedical applications

Peptide dendrimers as efficient and biocompatible gene delivery vectors: Synthesis and in vitro characterization

A novel peptide dendrimer LTP efficiently facilitates transfection of mammalian cells

Designed cell penetrating peptide dendrimers efficiently internalize cargo into cells

Dendrimers as carriers for siRNA delivery and gene silencing: a review

Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA

RNA interference-induced innate immunity, offtarget effect, or immune adjuvant?

Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application

Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality

Sequence-and targetindependent angiogenesis suppression by siRNA via TLR3

Topical treatment of herpes simplex virus infection with enzymatically created siRNA swarm

Inhibition of respiratory viruses by nasally administered siRNA

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems

Animal models for COVID-19

Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters